참고문헌
- Abedayo A, Onitillo, Jessica M, et al (2009). Breast cancer subtypes based on ER, PR and Her 2 expression : comparison of clinicopathological features and survival. Clinical Medicine and Research, 7, 4-13. https://doi.org/10.3121/cmr.2008.825
- Almasri NM, Al Hamad M (2005). Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res, 7, 598-604. https://doi.org/10.1186/bcr1200
- Nuclear Medicine, Oncology and Radiotherapy Institute (NORI) (2010-2012) Annual Report. Islamabad, 19.
- Asif HM, Sultana S, Akhtar N, et al (2014). Prevalence, risk factors and disease knowledge of breast cancer in Pakistan. Asian Pac J Cancer Prev, 15, 4411-16. https://doi.org/10.7314/APJCP.2014.15.11.4411
- Ayadi L, Khabir A, Amouri H, et al (2008). Correlation of HER- 2 over-expression with clinicopathological parameters in Tunisian breast carcinoma. World J Surg Oncol, 6, 112-9. https://doi.org/10.1186/1477-7819-6-112
- Bekir K, Mithat C, Chamlibel M, et al (2003). Prognostic factors affecting survival and disease free survival in lymph node negative breast carcinoma. J Sur Oncology, 83, 167-72. https://doi.org/10.1002/jso.10264
- Christine L, Carol A, Donald H (1989). Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer, 63, 181-7. https://doi.org/10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
- Cianfrocca M, Goldstein LJ (2004). Prognostic and predictive factors in early stage breast cancer. The oncologist, 9, 606-16. https://doi.org/10.1634/theoncologist.9-6-606
- Goksu SS, Tastekin D, Arslan D, et al (2014). Clinicopathological features and molecular subtypes of breast cancer in young women (age <35). Asian Pac J Cancer Prev, 15, 6665-8. https://doi.org/10.7314/APJCP.2014.15.16.6665
- Goldhrisch A, Glick JH, Gelber RD, et al (2005). Meeting highlights: International expert consensus on the primary therapy of early breast cancer. Ann Oncol, 16, 1659-583.
- Goldhrisch A, Wood WC, Geber RD, et al (2007).Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Annals of Oncology, 18, 1133-44. https://doi.org/10.1093/annonc/mdm271
- Goyanes RI, Perez XE, Rodriguez RC, et al (2010). Hormone receptors and other prognostic factors in breast cancer in Cuba. MEDICC review, 12, 36-40.
- Guth U, Wight E, Schotzau A, et al (2005). Breast carcinoma with non inflammatory skin involvement T4b: time to abandon an historic relic from TNM classification. Cancer, 104, 1862-70. https://doi.org/10.1002/cncr.21394
- Hussein O, Mosbah M, Farouk O, et al (2013).Hormone receptors and age distibution in breast cancer patients at university hospital in northern Egypt. Breast Cancer: Basic Clin Res, 7, 51-57.
- Jafari-Koshki T, Mansourian M, Mokarian F (2014). Exploring factors related to metastasis free survival in breast cancer patients using Bayesian cure models. Asian Pac J Cancer Prev, 15, 9673-78. https://doi.org/10.7314/APJCP.2014.15.22.9673
- Kaptain S, Tan LK, Chen B (2001). Her-2/neu and breast cancer. DiagnMolPathol, 10, 139-52.
- Kariya S, Ogawa Y, Nishioka A, et al (2005). Relationship between hormonal receptors, HER-2, p53 protein, bcl-2, and MIB-1 status and the antitumor effects of neoadjuvantanthracycline-based chemotherapy in invasive breast cancer patients. Radiat Med, 23, 189-94.
- Maksimovic S (2009). Prognostic value HER-2/neu expression inT1 to T3 breast cancer with axillary lymph node metastasis, Breast Cancer Res, 11 (Suppl 1), 9.
- Meng L, Maskarinec G, Wilkens L (1997). Ethnic differences and factors related to breast cancer survival in Hawaii. Int J Epidemiology, 26, 1151-58. https://doi.org/10.1093/ije/26.6.1151
- Michaelson JS, Silvesterstein M, Sgroi D, et al (2003). The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer, 98, 2133-43. https://doi.org/10.1002/cncr.11765
- Nair MK, Sankaranarayanan R, Nair KS, et al (1993). Overall survival from breast cancer in Kerala, India, in relation to menstrual, clinical and reproductive factors. Cancer, 71, 1791-6. https://doi.org/10.1002/1097-0142(19930301)71:5<1791::AID-CNCR2820710513>3.0.CO;2-W
- Rezaienzadeh A, Talei AR, Rejaeefard AR, et al (2012).Vascular invasion as an independent prognostic factor in lymph node negative invasive breast cancer. Asian Pacific J Cancer Prev, 13, 5767-72. https://doi.org/10.7314/APJCP.2012.13.11.5767
- Shim HJ, Kim SH, Kang BJ, et al (2014). Breast cancer recurrence according to molecular subtype. Asian Pac J Cancer Prev, 15, 5539-44. https://doi.org/10.7314/APJCP.2014.15.14.5539
- Tada K, Morizono H, Iijima K, et al (2008). Skin invasion and prognosis in node negative breast cancer: a retrospective study. World J Surg Oncol, 6.
- Vaz-Luis I, Ottessen RA, Hughes ME, et al (2012). Impact of hormone receptor status on breast cancer recurrence and clinical outcomes among patients with human epidermal growth factor 2 positive breast cancer in the National comprehensive cancer network. Breast Cancer Res, 14, R129. https://doi.org/10.1186/bcr3324
피인용 문헌
- Fitting Cure Rate Model to Breast Cancer Data of Cancer Research Center vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7923
- Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes vol.94, pp.32, 2015, https://doi.org/10.1097/MD.0000000000001359
- Survival probability and prognostic factors of Iranian breast cancer patients using cure rate model pp.1075122X, 2018, https://doi.org/10.1111/tbj.13120
- Metastatic and triple-negative breast cancer: challenges and treatment options vol.8, pp.5, 2018, https://doi.org/10.1007/s13346-018-0551-3